MAPT and Alzheimer disease: To diagnose of AD depends on the detection that we get from the CSF biomarker profile, which are the ratio Aβ 1–42/1–40, decrease in amyloid beta 1–42 (Aβ 1–42), and the increase of p-Tau and t-Tau levels (Ciaccio et al., 2021).